JANX vs. DICE, PAND, PRAX, SRRK, ALXO, CTLT, ELAN, ROIV, INSM, and LEGN
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include DICE Therapeutics (DICE), Pandion Therapeutics (PAND), Praxis Precision Medicines (PRAX), Scholar Rock (SRRK), ALX Oncology (ALXO), Catalent (CTLT), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Janux Therapeutics (NASDAQ:JANX) and DICE Therapeutics (NASDAQ:DICE) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
75.4% of Janux Therapeutics shares are held by institutional investors. 35.4% of Janux Therapeutics shares are held by insiders. Comparatively, 4.9% of DICE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
DICE Therapeutics has a net margin of 0.00% compared to Janux Therapeutics' net margin of -762.92%. Janux Therapeutics' return on equity of -13.49% beat DICE Therapeutics' return on equity.
In the previous week, Janux Therapeutics had 4 more articles in the media than DICE Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 0 mentions for DICE Therapeutics. Janux Therapeutics' average media sentiment score of 0.74 beat DICE Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.
Janux Therapeutics received 7 more outperform votes than DICE Therapeutics when rated by MarketBeat users. Likewise, 60.53% of users gave Janux Therapeutics an outperform vote while only 40.00% of users gave DICE Therapeutics an outperform vote.
Janux Therapeutics has a beta of 3.87, indicating that its stock price is 287% more volatile than the S&P 500. Comparatively, DICE Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
Janux Therapeutics currently has a consensus target price of $66.29, suggesting a potential upside of 23.90%. DICE Therapeutics has a consensus target price of $48.00, suggesting a potential upside of 0.95%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Janux Therapeutics is more favorable than DICE Therapeutics.
Janux Therapeutics has higher revenue and earnings than DICE Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than DICE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Janux Therapeutics beats DICE Therapeutics on 15 of the 18 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
